Bio Light files for stock offering

Bio Light, which increased its market value to $15m. since floatation, also reported developments at three of its four subsidiaries.

By SHARON WROBEL
April 17, 2006 06:45

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later

Bio Light Israeli Life Sciences Investments Ltd., which went public in December 2005 at a value of $10 million, announced on Sunday it was planning a second offering on the Tel Aviv Stock Exchange. Bio Light, which increased its market value to $15m. since floatation, also reported developments at three of its four subsidiaries. Obcure Ltd., which has discovered a treatment for obesity, has obtained US Food and Drug Administration approval to bypass Phase I safety trials and jump directly to Phase II clinical trials; Allergica Ltd., which is developing an allergy treatment, has hired Yaffa Beck as chairperson; and Zetiq Technologies Ltd. will launch its first preparations for identifying cancerous cells in a few months.

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS